SCHEMBL17239391

SCHEMBL17239391

C=CCC1/C=C\C(CC=C)C(CC=C)/C=C\C1CC=C

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17239392 1.00 NOS3 (0.30) NOS3NOS2
SCHEMBL17239402 0.80 ALDH1A1 (0.31)
SCHEMBL17239403 0.80 ALDH1A1 (0.31)
SCHEMBL17239396 0.76
SCHEMBL17239397 0.76
SCHEMBL14137725 0.71
SCHEMBL19621655 0.70
SCHEMBL8733766 0.67
SCHEMBL22618040 0.66
SCHEMBL1908312 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109970533-B (6R,10R) -6,10, 14-trimethylpentadecan-2-one prepared from (R) -6,10, 14-trimethylpentadeca-5-en-2-one 帝斯曼知识产权资产管理有限公司 2022-06-14 CN disclosed
EP-2935177-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS BV (NL) 2019-07-24 EP disclosed
EP-2935185-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14-TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE DSM IP ASSETS BV (NL) 2019-02-20 EP disclosed
EP-2935181-B1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES DSM IP ASSETS BV (NL) 2019-01-30 EP disclosed
EP-2935233-B1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS DSM IP ASSETS BV (NL) 2019-01-30 EP disclosed
EP-2935175-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-6,10,14-TRIMETYLPENTADEC-5-EN-2-ONE DSM IP ASSETS BV (NL) 2018-09-19 EP disclosed
EP-2935190-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDECA-3,5,9-TRIEN-2-ONE DSM IP ASSETS BV (NL) 2018-09-19 EP disclosed
EP-2935176-B1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM (R)-3,7-DIMETYLOCT-6-ENAL DSM IP ASSETS BV (NL) 2018-08-01 EP disclosed
EP-2935191-B1 PREPARATION OF (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE FROM 3,7-DIMETYLOCT-2-ENAL OR 3,7-DIMETYLOCTA-2,6-DIENAL DSM IP ASSETS BV (NL) 2018-08-01 EP disclosed
US-9611200-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10,14 trimetylpentadeca-5,9,13-trien-2-one or 6,10,14-trimetylpentadeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2017-04-04 US disclosed
US-9561989-B2 Process of asymmetric hydrogenation of ketals and acetals DSM IP ASSETS B.V. (NL) 2017-02-07 US disclosed
US-9452961-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2016-09-27 US disclosed
US-20160185683-A1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS DSM IP ASSETS B.V. (NL) 2016-06-30 US disclosed
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US disclosed
US-20150329456-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US disclosed
US-20150321971-A1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES DSM IP ASSETS B.V. (NL) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329456-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10,14 TRIMETYLPENTADECA-5,9,13-TRIEN-2-ONE OR 6,10,14-TRIMETYLPENTADECA-5,9-DIEN-2-ONE CYP3A5, ADRA1D, HTR5A NOS3 781/4885NOS2 1129/4885
US-20150321971-A1 EFFICIENT PROCESS OF ASYMMETRIC HYDROGENATION OF UNSATURATED KETONES USING ADDITIVES ADH5, ADH1A, ADH1C NOS3 3856/4885NOS2 3475/4885
US-20160185683-A1 PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS KAT5, AKR1D1, AKR1C2 NOS3 4174/4885NOS2 3735/4885
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE PDE12, CYP2D6, PDE9A NOS3 321/4885NOS2 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.